Vaccines empower the human immune system to protect against infection or disease. Vaccines against HIV are being developed, and tested in phases of clinical trials. At present, none of the HIV vaccines are commercially available.
Increasing number of HIV patients, technological advancement in HIV-AIDS diagnosis, increasing incidence of infectious diseases, rise in research activities for developing HIV vaccines and lack of awareness about the modes of transmission of the virus are expected to drive the market for HIV-AIDS testing. In addition, increasing awareness about HIV aids treatment options available in the market and cost effective drug therapies for HIV is expected to drive the HIV-AIDS testing market.
entists in the United Kingdom testing a combination of anti-HIV drugs have reported that a test patient showed no sign of the virus after treatment, making it a possible breakthrough in the hunt for a cure for HIV and AIDS.
The cumulative number HIV positives reported at the end of October 2007 was 223,501, including 62,838 AIDS cases and 22,205 recorded deaths. in 2007, the Ministry of Health, UNAIDS and WHO has prepared this updated assessment of the AIDS epidemic in China. The estimation result showed by the end of 2007, aproximately 700,000 are now HIV positive (range 550,000-850,000). The HIV infection rate among China's population is 0.05 per cent (range 0.04-0.07%). The estimated number of AIDS cases is 85,000 (range 80,000-90,000). The estimated new HIV infection in 2007 are 50,000 (range 40,000-60,000) and there are estimated 20,000 AIDS-related deaths (range 15,000-25,000). Among the living HIV positives, 40.6 per cent were infected through heterosexual transmission.